Peregrine Pharmaceuticals' Cotara Holds Promise for Treating Brain Cancer

Peregrine Pharmaceuticals has published a research article, titled "Safety and Feasibility of Convection-Enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients," in the journal Neurosurgery that validates the use of convection-enhanced delivery (CED) for administering Cotara to patients with brain cancer.

The article demonstrates that CED of Cotara resulted in accurate delivery of the prescribed dose of radiation and resulted in favorable tumor coverage while minimizing additional exposure to surrounding, healthy brain tissue.

CED provides a method of bypassing the blood-brain barrier for regional delivery of large molecule agents, such as Cotara, directly into the brain tumor region. The multicenter study, carried out at the Medical University of South Carolina, Barrow Neurological Institute, Temple University Hospital, University of Utah and Carolina Neurosurgery and Spine, is the largest study to date showing the safety and feasibility of administering a radiopharmaceutical via CED, the company said.